CenTrial Logo

Zavegepant Nasal Spray: A New Effective and Safe Treatment for Migraines


Clinical trial finds that Zavegepant nasal spray is effective for acute migraine treatment

Migraines can be debilitating and impact many aspects of daily life, such as work, school, and social activities. For those who suffer from migraines, relief can be hard to come by, especially when traditional oral medications don't work or cause unwanted side effects. However, a clinical trial has shown promise in providing a new treatment option for migraines.

Clinical Trial

The trial tested a nasal spray called Zavegepant, which is a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist. CGRP is a protein that is involved in the development of migraines, and the nasal spray works by blocking the receptors that CGRP binds to. This ultimately leads to a reduction in migraine symptoms.

The trial involved 1,405 participants who suffered from two to eight moderate or severe migraine attacks per month. Participants were randomly assigned to either receive the Zavegepant nasal spray or a placebo. They then self-treated a single migraine attack of moderate or severe pain intensity.


The results of the trial showed that two hours after taking the treatment dose, more participants in the Zavegepant group were pain-free and had freedom from their most bothersome symptoms compared to the placebo group. Specifically, 24% of participants in the Zavegepant group were pain-free compared to 15% in the placebo group. Additionally, 40% of participants in the Zavegepant group had freedom from their most bothersome symptom compared to 31% in the placebo group.

Are you interested in clinical trials near you?

You can receive free notification of a trial for this, or any other condition, by completing a short confidential health profile.
Find a clinical trial near me

The trial also found that Zavegepant was well-tolerated and had a favorable safety profile. The most common side effects reported were dysgeusia (abnormal taste sensation), nasal discomfort, and nausea, but these were generally mild and did not last long.

While this trial is promising, more research is needed to establish the long-term safety and effectiveness of Zavegepant in treating migraines. It is also important to note that this treatment may not work for everyone, and those who suffer from migraines should consult with their healthcare provider to determine the best course of treatment for their individual needs.


This clinical trial has shown promise in providing relief for those who suffer from migraines. The treatment was found to be effective in reducing pain and bothersome symptoms and was well-tolerated with mild side effects. While more research is needed, this new treatment option provides hope for those who struggle with migraines on a regular basis.


The Lancet, Mar-2023

Share this article with a friend:

Get emailed clinical trial results in the categories of your choice:
Free subscription to clinical trial results

Signup to be notified of clinical trials near you that match your condition

Signup and be matched to trials near you
This free service will notify you of current and future clinical trial matches.

This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. CenTrial Data Ltd. does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content. Treatments and clinical trials mentioned may not be appropriate or available for all trial participants. Outcomes from treatments and clinical trials may vary from person to person. Consult with your doctor as to whether a clinical trial is a suitable option for your condition. Assistance from generative AI tools may have been used in writing this article.